thelancet.com
Efficacy and safety of a 4-month quabodepistat, delamanid, and bedaquiline regimen for drug-susceptible pulmonary tuberculosis: a multicentre, open-label, randomised, proof-of-concept, non-inferiority...
In this proof-of-concept study, 4 months of DBQ showed a promising end-of-treatment
non-inferiority signal versus 6 months of RHEZ and was generally well tolerated. Our
results support further studies...